For the purpose of providing a GSK-3β inhibitor containing a 2-aminopyridine compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (IA):
wherein each symbol is as defined in the specification.
or a salt thereof or a prodrug thereof.
[EN] RADIOLABELED PHARMACEUTICALS AND METHODS OF MAKING AND USING SAME<br/>[FR] AGENTS PHARMACEUTIQUES RADIOMARQUÉS ET PROCÉDÉS D'UTILISATION DE CEUX-CI
申请人:UNIV YALE
公开号:WO2018152339A1
公开(公告)日:2018-08-23
In one aspect, the invention comprises compounds that bind to the synaptic vesicle protein SV2A and that can be useful as radiotracers for positron emission tomography. In another aspect, the invention comprises methods of imaging the brain, measuring synaptic density or diagnosing neurological diseases such as Alzheimer's disease, psychiatric disorders such as depression, and metabolic disorders such as diabetes comprising detecting the compounds of the invention by positron emission tomography (PET).
Bifunctional Iminophosphorane‐Catalyzed Enantioselective Nitroalkane Addition to Unactivated α,β‐Unsaturated Esters
作者:Daniel Rozsar、Alistair J. M. Farley、Iain McLauchlan、Benjamin D. A. Shennan、Ken Yamazaki、Darren James Dixon
DOI:10.1002/anie.202303391
日期:——
The first intermolecular enantioselectiveaddition of nitroalkanes to unactivated α,β-unsaturated esters is described, catalyzed by a bifunctional iminophosphorane (BIMP) superbase. This fundamental synthetically relevant transformation proceeds with high enantiomeric excesses and yields over a wide range of feedstock substrates, providing pharmaceutically relevant building blocks in a single step
Radiolabeled pharmaceuticals and methods of making and using same
申请人:YALE UNIVERSITY
公开号:US11518754B2
公开(公告)日:2022-12-06
In one aspect, the invention comprises compounds that bind to the synaptic vesicle protein SV2A and that can be useful as radiotracers for positron emission tomography. In another aspect, the invention comprises methods of imaging the brain, measuring synaptic density or diagnosing neurological diseases such as Alzheimer's disease, psychiatric disorders such as depression, and metabolic disorders such as diabetes comprising detecting the compounds of the invention by positron emission tomography (PET).